Xillix Technologies Corp.
TSX : XLX

Xillix Technologies Corp.

July 28, 2006 14:21 ET

Xillix to Host Second Quarter Conference Call Monday, July 31, 2006 at 5:00 p.m. E.S.T.

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - July 28, 2006) - Xillix Technologies Corp. (TSX:XLX), the world leader in fluorescence endoscopy, today announced that it intends to host a conference call on Monday July 31, 2006 at 5:00 p.m. E.S.T., 2:00 p.m. P.S.T, to discuss its financial results for the second quarter ended June 30, 2006. The Company intends to disclose its financial results via news release on July 31, 2006.

To access the conference call by telephone, dial 416-644-3424 or 1-866-250-4877. Please connect approximately ten minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Monday, August 7, 2006 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21197932 followed by the number sign.

A live audio webcast of the conference call will be available at www.xillix.com and www.newswire.ca. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web sites for 90 days.

About Xillix

Xillix Technologies Corp. is a Canadian medical device company and the world leader in fluorescence endoscopy for improved cancer detection. The Company's first-generation pioneering product, Xillix LIFE-Lung™ was approved by the FDA in 1996. Xillix's latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. An international multi-center lung cancer clinical trial of Onco-LIFE demonstrated a 325% per-lesion improvement in the detection of early lung cancer (moderate-severe dysplasia and carcinoma in situ) and a 250% per-patient improvement compared to white-light alone. Onco-LIFE is approved for sale in the United States for use in the lung cancer application and in Europe, Canada and Australia for both lung and GI applications. Onco-LIFE is compact, user-friendly and is compatible with a wide range of endoscopes and endoscopic accessories to help maximize global market acceptance.

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's Annual Information Form filed with securities regulatory authorities dated March 28, 2006.

Xillix is listed on the Toronto Stock Exchange under the trading symbol "XLX".


Contact Information